ArticleSarcoma2011
Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor.
Article in Sarcoma, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Connexin-43 in Cancer: Above and Beyond Gap Junctions!Cancers · 2024Review
- Suggested role for neutrophil extracellular trap formation in Ewing sarcoma immune microenvironment.Cancer science · 2024Article
- An immune-related gene signature for determining Ewing sarcoma prognosis based on machine learning.Journal of cancer research and clinical oncology · 2021Article
- Connexins in cancer: bridging the gap to the clinic.Oncogene · 2019Review
- Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat.Journal of adolescent and young adult oncology · 2017Article
- Connexin 43 (Cx43) Expression in Laryngeal Squamous Cell Carcinomas: Preliminary Data on Its Possible Prognostic Role.Head and neck pathology · 2016Article
- Evaluation of PAX8 Expression and Its Potential Diagnostic and Prognostic Value in Renal and Extra-Renal Ewing Sarcomas/PNETs.Pathology oncology research : POR · 2016Article
- Clinical significance of preoperative serum high density lipoprotein cholesterol levels in soft tissue sarcoma.Medicine · 2015Article
- Gene expression signatures of primary and metastatic uterine leiomyosarcoma.Human pathology · 2014Article
- Improved survival modeling in cancer research using a reduced piecewise exponential approach.Statistics in medicine · 2014Article
- Possible role of hemichannels in cancer.Frontiers in physiology · 2014Article
- Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.Frontiers in oncology · 2013Article
- Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test.Statistics in biopharmaceutical research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Connexins (Cxs) are building unit proteins of gap junctions (GJs) that are prognostic markers in carcinomas. To investigate the role of Cx in Ewing sarcoma (EWS)/primitive neuroectodermal tumor (PNET), we examined the expression of Cx43 and Cx26 in 36 EWS/PNETs and found (1) cytoplasmic Cx43 reactivity in 28/36 (78%) cases. (2) Cx43 score was significantly correlated with overall survival (P = .025). The average scores for patients alive and dead at 3 years are 46.08 and 96.98 (P = .004) at 5 years are 46.06 and 96.42 (P = .002). (3) Metastasis had a significant effect on the overall survival (P = .003). (4) Cytoplasmic Cx26 reactivity was detected in 2 of 36 (6%) patients who died with metastasis. Our results suggest a possible oncogenic and prognostic role for Cx43 and Cx26 in EWS/PNET. The lack of membranous immunoreactivity suggests that the effect of Cx in EWS/PNET is via a GJ function-independent mechanism.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.